V. Endometriumkarzinom

1. Statistik Austria, Österreichisches Krebsregister (Stand: 13. 9. 2011, erstellt am 23. 9. 2011)
2. Creasman W.T., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Heintz A.P. et al.: Carcinoma of the corpus uteri. J Epidemiol Biostat 2001; 6:47-86
3. Sorosky J.I.: Endometrial Cancer. Review. J Obstet Gynecol 2008; 111:436-447
4. Courneya K.S., Karvinen K.H., Campbell K.L., Pearcey R.G., Dundas G., Capstick V. et al.: Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol 2005; 97:422-430
5. Ferguson S.E., Soslow R.A., Amsterdam A., Barakat R.R.: Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 2006; 101:322-3262159-66
6. Smith-Bindman R., Weiss R., Feldstein V.: How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004; 24:558
7. Ben-Arie A., Goldchmit C., Laviv Y., Levy R., Caspi B., Huszar M., Dgani R., Hagay Z.: The malignant potential of endometrial polyps. Eur J Obstet Gynecol Reprod Biol 2004 Aug 10; 115 (2):206-210
8. Aslan D.L., Crapanzano J.P., Harshan M., Erroll M., Vakil B., Pirog E.C.: The Bethesda System 2001: recommendation for reporting of benign appearing endometrial cells in Pap tests of women age 40 years and older leads to unwarranted surveillance when followed without clinical qualifiers. Gynecol Oncol 2007 Oct; 107 (1):86-93. Epub 2007 Jun 29
9. Gull B., Carlsson S., Karlsson B., Ylöstalo P., Milsom I., Granberg S.: Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: is it always necessary to perform an endometrial biopsy? Am J Obstet Gynecol 2000 Mar; 182 (3):509-515
10. Timmermans A., Opmeer B.C., Khan K.S. et al.: Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 2010; 116:160
11. Baak J.P., Mutter G.L., Robbey Set al.: The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005; 103:2304
12. Kurman R.J., Kaminski P.F., Norris H.J.: The behavior of endometrial hyperplasia. A long-term study of „untreated“ hyperplasia in 170 patients. CA Cancer J Clin 1985; 56:403
13. Ronnett B.M., Kurman R.J.: Precursor Lesions of Endometrial Carcinoma. In: Blausteins Pathology of the female genital tract. Editor: Robert J.Kurman, Fifth Edition 2002, Springer Verlag, New York, Berlin, Heidelberg
14. Lacey J.V. Jr., Sherman M.E., Rush B.B. et al.: Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010; 28:788
15. Trimble C.L.: Atypical endometrial Hyperplasia: a tough call. Int J Gynecol Cancer 2005; 15:401
16. Wright T.C. Jr., Massad S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D., for the 2006 American society for Colposcopy and Cervical Pathology – sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening test. Am J Obstet Gynecol 2007 Oct; 346-355
17. Beal H.N., Stone J., Beckmann M.J., McAsey M.E.: Endometrial cells identified in cervical cytology in women > or = 40 years of age: criteria for appropriate endometrial evaluation. Am J Obstet Gynecol 2007 Jun; 196 (6):568.e1-5; discussion 568.e5-6
18. Parslov M., Lifegaard Ø., Klintrop S., Pedersen B., Jønsson L., Eriksen P. S., Ottesen B.: Risk factors among young women with endometrial cancer: A Danish case-control study. Am J Obstet Gynecol 2000; 182:23-29
19. Ben-Arie A., Tamir S., Dubnik S., Gemer O., Ben Sushan A., Dgani R., Peer G., Barnett-Griness O., Lavie O.: Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer? Int J Gynecol Cancer 2008 Jul-Aug; 18 (4):813-819
20. Dijkhuizen F.P., Mol B.W., Brölman H.A., Heintz A.P.: The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 89:1765
21. Egle D., Grissemann B., Zeimet A.G., Müller-Holzner E., Marth C.: Validation of intraoperative risk assessment on frozen section for surgical management of endometrial carcinoma. Gynecol Oncol 2008 Sep; 110 (3):286-92. Epub 2008 Jul 23
22. Pristauz G., Bader A.A., Regitnig P., Haas J., Winter R., Tamussino K. How accurate is frozen section histology of pelvic lymph nodes in patients with endometrial cancer? Gynecol Oncol 2009 Oct; 115 (1):12-17
23. Franchi M., Ghezzi F., Melpignano M. et al.: Clinical value of intraoperative gross examination in endometrial cancer. Gynecol Oncol 2000; 76:357
24. Leitao M.M. Jr., Kehoe S., Barakat R.R. et al.: Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2008; 111:244
25. Kwon J.S., Francis J.A., Qiu F. et al.: When is a pathology review indicated in endometrial cancer? Obstet Gynecol 2007; 110:1224
26. Pecorelli S.: Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol and Obstet 2009; 105:103-104
27. Lindauer J., Fowler L.M., Manolitsas T.P., Copeland L.J., Eaton L.A., Ramirez N.C., Crohn D.E.: Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer? Gynecol Oncol 2003 Dec; 91 (3):547-551
28. Silverman M.B., Roche P.C., Kho R.M., Keeney G.L., Li H., Podratz K.C.: Molecular and cytokinetic pretreatment risk in endometrial carcinoma. Gynecol Oncol 2000 Apr; 77 (1):1-7
29. Fogel M., Gutwein P., Mechtersheimer S., Riedle S., Stoeck A., Smirniv A., Edler L., Ben-Arie A., Huszar M., Altevogt P.: L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003 Sep 13; 362 (9387):869-975
30. Gehrig P.A., Van Le L., Olatidoye B., Geradts J.: Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999 Nov 15; 86 (10):2083-2089
31. Karen Lu, ASCO 2011, 01009
32. Cheung et al., Cancer Discovery 2011 (in press)
33. May K., Bryant A., Dickinson H.O., Kehoe S., Morrison J.: Lymphadenectomy for the management of endometrial cancer. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007585. DOI: 10.1002/14651858. CD007585.pub2
34. Watanabe Y., Satou T., Nakai H., Etoh T., Dote K., Fujinami N., Hoshiai H.: Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol 2010; 116 (5):1027
35. Todo Y., Kato H., Kaneuchi M., Watari H., Takeda M.,Sakuragi N.: Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010 Apr 3; 375 (9721):1165-72. Epub 2010 Feb 24
36. Lambrou N.C., Gomez-Martin O., Mirhashemi R., Beach H., Salom E., Almeida-Parra Z., Penalver M.: Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 2004 Jun; 93 (3):653-658
37. Havrilesky L.J., Cragun L.M., Calingaert B., Alvarez Secord A., Valea F.A., Clarke-Pearson D.L, Berchuck A., Soper J.T.: The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol 2007 Feb; 104 (2):401-405
38. Maltaris T., Boehm D., Dittrich R., Seufert R., Koelbl H.: Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol 2006 Dec; 103 (3):1109-1121. Epub 2006 Sep 25. Review
39. Cochrane Database, Syst Rev 2000; (2):CD001040
40. Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Wárlám-Rodenhuis C.C., De Winter K.A., Lutgens L.C., van den Bergh A.C., van de Steen-Banasik E., Beerman H., van Lent M.: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: a multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet Apr 2000; 355 (9213):1404-1411
41. Nout R.A., Putter H., Jürgenliemk-Schulz I.M.: Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial. J Clin Oncol 2008; 26, Abstr.LBA503
42. Johnson N., Cornes P.: Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007; 114:1313-20
43. Randall M.E., Spirtos N.M., Dvoretsky P.: Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. J Natl Cancer Inst Monogr 1995; 19: 13-5
44. ASTEC/EN.5 Study Group, Blake P., Swart A.M., Orton J., Kitchener H., Whelan T., Lukka H., Eisenhauer E., Bacon M., Tu D., Parmar M.K., Armos C., Quian W.: Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): polled trial results, systematic review, and meta analysis. Lancet 2009 Jan 10; 373 (9658):137-46. Epub 2008 Dec 16
45. Hogberg T., Rosenberg P., Kristensen G. et al.: A randomized phase III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early stage high-risk endometrial cancer (NSGO-EC-9505/EORTC 55991). J Clin Oncol 2007; 25:247s
46. Hogberg T.: Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Clin Oncol (R Coll Radiol) 2008 Aug; 20 (6):463-9. Epub 2008 May 7
47. Kong A. et al.: Cochrane Database Syst Rev 2007 Apr 18; (2):CD003916
48. Humber C.E., Tierney J.F., Symonds R.P., Collingwood M., Kirwan J., Williams C., Green J.A.: Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane Collaboration. Ann Oncol 2007 Mar; 18 (3):409-420
49. Thipgen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., Liao S.: Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004
Oct 1; 22 (19):3902-3908
50. Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L., Gallion H.: Phase III rancomized trial of doxorubicin plus cisplatin versus doxorubicin plus 24 h paclitaxel plus filgastrim in endometrial carcinoma: a Gynecologic Oncology Group Study. Ann Oncol 2004 Aug; 15 (8):1173-1178
51. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., Kline R., Burger R.A., Goodman A., Burks R.T.: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgastrim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004 Jun 1; 22 (11):2159-2166